Pular para o conteúdo
Doença das células dos cornos anteriores
ORPHA:98503CID-10 · G12.2CID-11 · 8B60DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Muscular

Doença neurológica que afeta as células nervosas responsáveis pelos movimentos.

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A esclerose lateral primária juvenil é um distúrbio raro caracterizado por fraqueza progressiva e rigidez (espasticidade) dos músculos dos braços, pernas e face. As características desse distúrbio são causadas por dano aos neurônios motores, que são células nervosas especializadas no cérebro e na medula espinhal que controlam o movimento muscular.

Os sintomas da esclerose lateral primária juvenil começam na primeira infância e progridem lentamente ao longo de muitos anos. Os sintomas iniciais incluem descoordenação, fraqueza muscular e espasticidade nas pernas, e dificuldade de equilíbrio. À medida que os sintomas progridem, a espasticidade se espalha para os braços e mãos e as pessoas com a condição desenvolvem fala arrastada, baba, dificuldade para engolir e incapacidade de caminhar.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

Doença neurológica que afeta as células nervosas responsáveis pelos movimentos.

Pesquisas ativas
65 ensaios
213 total registrados no ClinicalTrials.gov
Publicações científicas
6.722 artigos
Último publicado: 2026
🏥
SUS: Cobertura mínimaScore: 15%
2 procedimentos SIGTAPCID-10: G12.2
🇧🇷Dados SUS / DATASUS
EXAMES E PROCEDIMENTOS RELACIONADOS (2)
•
Sequenciamento completo do exoma (WES)
•
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
114 sintomas
💪
Músculos
109 sintomas
🦴
Ossos e articulações
47 sintomas
🫁
Pulmão
18 sintomas
👁️
Olhos
17 sintomas
😀
Face
15 sintomas

+ 290 sintomas em outras categorias

Características mais comuns

—
Sinal de Hoffmann
—
Paraparesia espástica
—
Anormalidade no teste de função pulmonar
—
Perda de peso
—
Deformidades congênitas de contratura do pé
—
Laringoespasmo
666sintomas
Sem dados (666)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 666 características clínicas mais associadas, ordenadas por frequência.

Sinal de HoffmannHoffmann sign
Paraparesia espásticaSpastic paraparesis
Anormalidade no teste de função pulmonarAbnormality on pulmonary function testing
Perda de pesoWeight loss
Deformidades congênitas de contratura do péCongenital foot contraction deformities

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico6.722PubMed
Últimos 10 anos200publicações
Pico2026125 papers
Linha do tempo
2026Hoje · 2026🧪 1987Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

69 genes identificados com associação a esta condição.

GARS1Glycine--tRNA ligaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2D

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 5ACharcot-Marie-Tooth disease type 2Dspinal muscular atrophy, infantile, James typeneuronopathy, distal hereditary motor, type 5
HGNC:4162UniProt:P41250
PON3Serum paraoxonase/lactonase 3Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Synthesis of 5-eicosatetraenoic acids
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
120.6 TPM
Pituitária
41.2 TPM
Ovário
28.1 TPM
Testículo
18.8 TPM
Pulmão
11.3 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:9206UniProt:Q15166
OPTNOptineurinCandidate gene tested inTolerante
VIAS BIOLÓGICAS (8)
PINK1-PRKN Mediated MitophagyActivation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 TNFR1-induced proapoptotic signalingRegulation of TNFR1 signaling
MECANISMO DE DOENÇA

Glaucoma 1, open angle, E

A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
367.0 TPM
Artéria tibial
110.7 TPM
Ovário
99.9 TPM
Testículo
99.0 TPM
Tecido adiposo
91.4 TPM
OUTRAS DOENÇAS (4)
OPTN-related open angle glaucomaamyotrophic lateral sclerosis type 12amyotrophic lateral sclerosisglaucoma, normal tension, susceptibility to
HGNC:17142UniProt:Q96CV9
PPARGC1APeroxisome proliferator-activated receptor gamma coactivator 1-alphaCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
Expression of BMAL (ARNTL), CLOCK, and NPAS2Heme signalingTranscriptional activation of mitochondrial biogenesisRORA,B,C and NR1D1 (REV-ERBA) regulate gene expressionRegulation of RUNX2 expression and activity
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
17.3 TPM
Coração - Átrio
13.5 TPM
Rim - Medula
12.6 TPM
Músculo esquelético
11.0 TPM
Glândula salivar
10.8 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:9237UniProt:Q9UBK2
PLEKHG5Pleckstrin homology domain-containing family G member 5Candidate gene tested inTolerante
VIAS BIOLÓGICAS (5)
G alpha (12/13) signalling eventsNRAGE signals death through JNKRND1 GTPase cycleRND3 GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 4

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMNR4 is characterized by childhood onset, generalized muscle weakness and atrophy with denervation and normal sensation. Bulbar symptoms and pyramidal signs are absent.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
244.8 TPM
Cérebro - Hemisfério cerebelar
198.3 TPM
Skin Not Sun Exposed Suprapubic
118.5 TPM
Skin Sun Exposed Lower leg
101.4 TPM
Baço
78.8 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (2)
Charcot-Marie-Tooth disease recessive intermediate Cneuronopathy, distal hereditary motor, autosomal recessive 4
HGNC:29105UniProt:O94827
SLC52A3Solute carrier family 52, riboflavin transporter, member 3Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Vitamin B2 (riboflavin) metabolism
MECANISMO DE DOENÇA

Brown-Vialetto-Van Laere syndrome 1

A rare neurologic disorder characterized by sensorineural hearing loss and a variety of cranial nerve palsies, which develop over a relatively short period of time in a previously healthy individual. Sensorineural hearing loss may precede the neurological signs. The course is invariably progressive, but the rate of decline is variable within and between families. With disease evolution, long tract signs, lower motor neuron signs, cerebellar ataxia and lower cranial nerve (III-VI) palsies develop, giving rise to a complex picture resembling amyotrophic lateral sclerosis. Diaphragmatic weakness and respiratory compromise are some of the most distressing features, leading to recurrent chest infections and respiratory failure, which are often the cause of patients' demise.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
76.2 TPM
Rim - Medula
9.0 TPM
Próstata
8.7 TPM
Rim - Córtex
7.7 TPM
Intestino delgado
7.0 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (3)
progressive bulbar palsy of childhoodBrown-Vialetto-van Laere syndrome 1Brown-Vialetto-van Laere syndrome 2
HGNC:16187UniProt:Q9NQ40
SPG7Mitochondrial inner membrane m-AAA protease component parapleginCandidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Processing of SMDT1Mitochondrial protein degradation
MECANISMO DE DOENÇA

Spastic paraplegia 7, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG7 is a complex form. Additional clinical features are cerebellar syndrome, supranuclear palsy, and cognitive impairment, particularly disturbance of attention and executive functions.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
63.6 TPM
Cerebelo
50.5 TPM
Cérebro - Hemisfério cerebelar
47.8 TPM
Ovário
47.7 TPM
Cervix Endocervix
43.6 TPM
OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 7lateral sclerosis
HGNC:11237UniProt:Q9UQ90
AGTPBP1Cytosolic carboxypeptidase 1Candidate gene tested inRestrito
VIAS BIOLÓGICAS (1)
Carboxyterminal post-translational modifications of tubulin
MECANISMO DE DOENÇA

Neurodegeneration, childhood-onset, with cerebellar atrophy

An autosomal recessive disorder characterized by early onset of progressive neurodegeneration affecting the central and peripheral nervous systems. Clinical features include global developmental delay, impaired intellectual development, poor or absent speech, and motor abnormalities. Brain imaging shows cerebellar atrophy. Death in childhood may occur.

INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
neurodegeneration, childhood-onset, with cerebellar atrophypontocerebellar hypoplasia type 1
HGNC:17258UniProt:Q9UPW5
TBCETubulin-specific chaperone ECandidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Post-chaperonin tubulin folding pathway
MECANISMO DE DOENÇA

Hypoparathyroidism-retardation-dysmorphism syndrome

An autosomal recessive multisystem disorder characterized by hypoparathyroidism, intrauterine and postnatal growth retardation, psychomotor retardation, epilepsy, microcephaly, and facial dysmorphism.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
38.8 TPM
Cérebro - Hemisfério cerebelar
35.3 TPM
Fibroblastos
31.5 TPM
Artéria tibial
31.4 TPM
Cerebelo
31.3 TPM
OUTRAS DOENÇAS (4)
autosomal recessive Kenny-Caffey syndromeencephalopathy, progressive, with amyotrophy and optic atrophyhypoparathyroidism-retardation-dysmorphism syndromeearly-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome
HGNC:11582UniProt:Q15813
SOD1Superoxide dismutase [Cu-Zn]Candidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Detoxification of Reactive Oxygen SpeciesPlatelet degranulation
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 1

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
378.5 TPM
Glândula adrenal
377.5 TPM
Brain Frontal Cortex BA9
347.6 TPM
Hipotálamo
301.1 TPM
Brain Spinal cord cervical c-1
289.0 TPM
OUTRAS DOENÇAS (3)
spastic tetraplegia and axial hypotonia, progressiveamyotrophic lateral sclerosis type 1amyotrophic lateral sclerosis
HGNC:11179UniProt:P00441
CFAP410Cilia- and flagella-associated protein 410Candidate gene tested inTolerante
MECANISMO DE DOENÇA

Retinal dystrophy with or without macular staphyloma

An ocular disorder characterized by decreased vision which worsen over time, and dystrophic changes in the retina, such as retinal pigment epithelium mottling and vessel narrowing. Macular staphyloma, without high myopia, is present in some patients.

INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (4)
axial spondylometaphyseal dysplasiaretinal dystrophy with or without macular staphylomaamyotrophic lateral sclerosiscone-rod dystrophy
HGNC:1260UniProt:O43822
GLT8D1Glycosyltransferase 8 domain-containing protein 1Candidate gene tested inTolerante
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
92.2 TPM
Pituitária
87.6 TPM
Testículo
80.6 TPM
Tireoide
75.7 TPM
Nervo tibial
71.0 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:24870UniProt:Q68CQ7
HNRNPA1Heterogeneous nuclear ribonucleoprotein A1Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (5)
FGFR2 alternative splicingmRNA Splicing - Major PathwaymRNA PolyadenylationProcessing of Capped Intron-Containing Pre-mRNADengue Virus-Host Interactions
MECANISMO DE DOENÇA

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3

An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1092.5 TPM
Linfócitos
728.9 TPM
Cervix Ectocervix
629.5 TPM
Cervix Endocervix
629.4 TPM
Útero
591.7 TPM
OUTRAS DOENÇAS (5)
inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3amyotrophic lateral sclerosis type 20Finnish upper limb-onset distal myopathyamyotrophic lateral sclerosis
HGNC:5031UniProt:P09651
DAOD-amino-acid oxidaseCandidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Glyoxylate metabolism and glycine degradationPeroxisomal protein import
EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
40.1 TPM
Cérebro - Hemisfério cerebelar
26.7 TPM
Fígado
23.7 TPM
Brain Spinal cord cervical c-1
15.7 TPM
Substância negra
5.9 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:2671UniProt:P14920
NEK1Serine/threonine-protein kinase Nek1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Regulation of pyruvate metabolism
MECANISMO DE DOENÇA

Short-rib thoracic dysplasia 6 with or without polydactyly

A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
63.9 TPM
Testículo
14.3 TPM
Cerebelo
13.0 TPM
Cérebro - Hemisfério cerebelar
13.0 TPM
Ovário
12.2 TPM
OUTRAS DOENÇAS (5)
orofaciodigital syndrome type IIshort-rib thoracic dysplasia 6 with or without polydactylyamyotrophic lateral sclerosisshort rib-polydactyly syndrome, Majewski type
HGNC:7744UniProt:Q96PY6
GLE1mRNA export factor GLE1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Transport of Mature mRNA derived from an Intron-Containing Transcript
MECANISMO DE DOENÇA

Lethal congenital contracture syndrome 1

A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy, and congenital non-progressive joint contractures (arthrogryposis). The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS1 patients manifest early fetal hydrops and akinesia, micrognathia, pulmonary hypoplasia, pterygia, and multiple joint contractures. It leads to prenatal death.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
66.4 TPM
Linfócitos
52.3 TPM
Cérebro - Hemisfério cerebelar
35.0 TPM
Fibroblastos
31.7 TPM
Cerebelo
30.4 TPM
OUTRAS DOENÇAS (3)
lethal congenital contracture syndrome 1lethal arthrogryposis-anterior horn cell disease syndromeamyotrophic lateral sclerosis
HGNC:4315UniProt:Q53GS7
PON2Serum paraoxonase/arylesterase 2Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
Synthesis of 5-eicosatetraenoic acids
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
151.8 TPM
Brain Caudate basal ganglia
141.5 TPM
Brain Nucleus accumbens basal ganglia
132.8 TPM
Glândula adrenal
123.5 TPM
Cérebro - Amígdala
113.8 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:9205UniProt:Q15165
TAF15TATA-binding protein-associated factor 2NCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (9)
Regulation of TP53 Activity through PhosphorylationRNA Polymerase II Promoter EscapeRNA Polymerase II HIV Promoter EscapeRNA Polymerase II Pre-transcription EventsHIV Transcription Initiation
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
199.6 TPM
Testículo
191.9 TPM
Fibroblastos
180.0 TPM
Esôfago - Muscular
141.2 TPM
Útero
137.9 TPM
OUTRAS DOENÇAS (2)
extraskeletal myxoid chondrosarcomaamyotrophic lateral sclerosis
HGNC:11547UniProt:Q92804
SLC25A46Mitochondrial outer membrane protein SLC25A46Candidate gene tested inTolerante
MECANISMO DE DOENÇA

Neuropathy, hereditary motor and sensory, 6B, with optic atrophy

An autosomal recessive neurologic disorder characterized by early-onset optic atrophy, progressive visual loss, and peripheral sensorimotor neuropathy manifesting as axonal Charcot-Marie-Tooth disease, with variable age at onset and severity. Charcot-Marie-Tooth disease is a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. It is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies and primary peripheral axonal neuropathies. Peripheral axonal neuropathies are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, and normal or slightly reduced nerve conduction velocities.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.0 TPM
Cérebro - Hemisfério cerebelar
31.7 TPM
Fibroblastos
27.1 TPM
Cerebelo
25.2 TPM
Nervo tibial
21.7 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (4)
neuropathy, hereditary motor and sensory, type 6Bpontocerebellar hypoplasia, type 1Epontocerebellar hypoplasia type 1hereditary motor and sensory neuropathy type 6
HGNC:25198UniProt:Q96AG3
TARDBPTAR DNA-binding protein 43Candidate gene tested inAltamente restrito
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 10

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
121.2 TPM
Cérebro - Hemisfério cerebelar
114.9 TPM
Útero
114.8 TPM
Ovário
111.4 TPM
Tireoide
105.5 TPM
OUTRAS DOENÇAS (3)
amyotrophic lateral sclerosis type 10amyotrophic lateral sclerosisfrontotemporal dementia with motor neuron disease
HGNC:11571UniProt:Q13148
TBK1Serine/threonine-protein kinase TBK1Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
PINK1-PRKN Mediated MitophagyDDX58/IFIH1-mediated induction of interferon-alpha/betaSARS-CoV-2 activates/modulates innate and adaptive immune responsesTRAF3-dependent IRF activation pathwayTRAF6 mediated IRF7 activation
MECANISMO DE DOENÇA

Glaucoma 1, open angle, P

A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. GLC1P is characterized by early onset, thin central corneas and low intraocular pressure.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
50.3 TPM
Testículo
42.8 TPM
Fibroblastos
35.0 TPM
Pulmão
30.8 TPM
Útero
30.3 TPM
OUTRAS DOENÇAS (6)
autoinflammation with arthritis and vasculitisfrontotemporal dementia and/or amyotrophic lateral sclerosis 4amyotrophic lateral sclerosisfrontotemporal dementia with motor neuron disease
HGNC:11584UniProt:Q9UHD2
PRPHPeripherinCandidate gene tested inTolerante
MECANISMO DE DOENÇA

Retinitis pigmentosa 7

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
46.2 TPM
Cólon sigmoide
25.3 TPM
Cólon transverso
11.4 TPM
Cervix Ectocervix
6.4 TPM
Esôfago - Muscular
6.0 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (2)
amyotrophic lateral sclerosisamyotrophic lateral sclerosis type 1
HGNC:9461UniProt:P41219
ERLIN2Erlin-2Candidate gene tested inTolerante
VIAS BIOLÓGICAS (3)
AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)ABC-family proteins mediated transportDefective CFTR causes cystic fibrosis
MECANISMO DE DOENÇA

Spastic paraplegia 18B, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG18B is a severe form with onset in early childhood. Most affected individuals have severe psychomotor retardation. Some may develop significant joint contractures.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
29.8 TPM
Tireoide
22.2 TPM
Ovário
21.0 TPM
Útero
18.9 TPM
Nervo tibial
18.8 TPM
OUTRAS DOENÇAS (4)
spastic paraplegia 18a, autosomal dominantjuvenile primary lateral sclerosishereditary spastic paraplegia 18recessive intellectual disability-motor dysfunction-multiple joint contractures syndrome
HGNC:1356UniProt:O94905
FUSRNA-binding protein FUSCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (4)
mRNA Splicing - Major PathwaymRNA PolyadenylationProcessing of Capped Intron-Containing Pre-mRNADengue Virus-Host Interactions
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
193.2 TPM
Cérebro - Hemisfério cerebelar
173.6 TPM
Cerebelo
159.0 TPM
Cervix Ectocervix
155.5 TPM
Cervix Endocervix
152.7 TPM
OUTRAS DOENÇAS (7)
tremor, hereditary essential, 4amyotrophic lateral sclerosis type 6myxoid/round cell liposarcomajuvenile amyotrophic lateral sclerosis
HGNC:4010UniProt:P35637
SMN2Survival motor neuron proteinCandidate gene tested inModerado
VIAS BIOLÓGICAS (2)
snRNP AssemblySARS-CoV-2 modulates host translation machinery
MECANISMO DE DOENÇA

Spinal muscular atrophy 1

A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cervix Ectocervix
4.9 TPM
Ovário
4.9 TPM
Testículo
4.5 TPM
Útero
4.4 TPM
Linfócitos
4.2 TPM
OUTRAS DOENÇAS (4)
spinal muscular atrophy, type IVspinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:11118UniProt:Q16637
EXOSC9Exosome complex component RRP45Candidate gene tested inTolerante
VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1D

An autosomal recessive neurologic disorder with onset at birth or in infancy, and characterized by progressive axonal motor neuronopathy, severe generalized hypotonia, respiratory insufficiency, and cerebellar atrophy. Death in childhood may occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
43.9 TPM
Testículo
34.6 TPM
Fibroblastos
34.4 TPM
Nervo tibial
24.9 TPM
Cérebro - Hemisfério cerebelar
23.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Dpontocerebellar hypoplasia type 1
HGNC:9137UniProt:Q06265
NAIPBaculoviral IAP repeat-containing protein 1Candidate gene tested inTolerante
EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
5.8 TPM
Baço
3.8 TPM
Pulmão
1.3 TPM
Testículo
1.0 TPM
Fallopian Tube
0.9 TPM
OUTRAS DOENÇAS (3)
spinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:7634UniProt:Q13075
SETXHelicase senataxinCandidate gene tested inAltamente restrito
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAN2 is an autosomal recessive form associated with peripheral neuropathy and elevated serum alpha-fetoprotein, immunoglobulins and, less commonly, creatine kinase levels. Some SCAN2 patients manifest oculomotor apraxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
50.4 TPM
Linfócitos
39.4 TPM
Tireoide
36.1 TPM
Baço
32.8 TPM
Pulmão
25.9 TPM
OUTRAS DOENÇAS (2)
spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2amyotrophic lateral sclerosis type 4
HGNC:445UniProt:Q7Z333
CYLDUbiquitin carboxyl-terminal hydrolase CYLDDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (6)
NOD1/2 Signaling PathwayUb-specific processing proteasesNegative regulators of DDX58/IFIH1 signalingTNFR1-induced proapoptotic signalingTNFR1-induced NF-kappa-B signaling pathway
MECANISMO DE DOENÇA

Cylindromatosis, familial

A disorder characterized by multiple skin tumors that develop from skin appendages, such as hair follicles and sweat glands. Affected individuals typically develop large numbers of tumors called cylindromas that arise predominantly in hairy parts of the body with approximately 90% on the head and neck. In severely affected individuals, cylindromas may combine into a confluent mass which may ulcerate or become infected (turban tumor syndrome). Individuals with familial cylindromatosis occasionally develop other types of tumors including spiradenomas that begin in sweat glands, and trichoepitheliomas arising from hair follicles.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
45.5 TPM
Artéria tibial
26.4 TPM
Baço
25.6 TPM
Aorta
24.3 TPM
Pituitária
22.6 TPM
OUTRAS DOENÇAS (5)
trichoepithelioma, multiple familial, 1frontotemporal dementia and/or amyotrophic lateral sclerosis 8familial cylindromatosisBrooke-Spiegler syndrome
HGNC:2584UniProt:Q9NQC7
SIGMAR1Sigma non-opioid intracellular receptor 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Potential therapeutics for SARS
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 16, juvenile

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
143.9 TPM
Fígado
106.6 TPM
Cervix Ectocervix
101.1 TPM
Cervix Endocervix
93.5 TPM
Útero
86.8 TPM
OUTRAS DOENÇAS (3)
amyotrophic lateral sclerosis type 16autosomal recessive distal spinal muscular atrophy 2juvenile amyotrophic lateral sclerosis
HGNC:8157UniProt:Q99720
SQSTM1Sequestosome-1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (9)
PINK1-PRKN Mediated MitophagyPexophagyNF-kB is activated and signals survivalp75NTR recruits signalling complexesInterleukin-1 signaling
MECANISMO DE DOENÇA

Paget disease of bone 3

A disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
155.2 TPM
Artéria tibial
140.4 TPM
Aorta
135.6 TPM
Fibroblastos
134.0 TPM
Glândula adrenal
131.3 TPM
OUTRAS DOENÇAS (8)
Paget disease of bone 3myopathy, distal, with rimmed vacuolesneurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 3
HGNC:11280UniProt:Q13501
ASCC1Activating signal cointegrator 1 complex subunit 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
ALKBH3 mediated reversal of alkylation damage
MECANISMO DE DOENÇA

Barrett esophagus

A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

OUTRAS DOENÇAS (3)
spinal muscular atrophy with congenital bone fractures 2Barrett esophagusprenatal-onset spinal muscular atrophy with congenital bone fractures
HGNC:24268UniProt:Q8N9N2
TSEN54tRNA-splicing endonuclease subunit Sen54Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
tRNA processing in the nucleus
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 4

A disorder characterized by an abnormally small cerebellum and brainstem, severe neonatal encephalopathy, microcephaly, myoclonus and muscular hypertonia. There is a severe inferior olivary and pontine neuronal loss and a diffuse white matter gliosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
61.6 TPM
Cérebro - Hemisfério cerebelar
59.4 TPM
Baço
34.8 TPM
Tireoide
34.5 TPM
Próstata
33.2 TPM
OUTRAS DOENÇAS (4)
pontocerebellar hypoplasia type 4pontocerebellar hypoplasia type 2Apontocerebellar hypoplasia type 5pontocerebellar hypoplasia type 2
HGNC:27561UniProt:Q7Z6J9
HSPB8Heat shock protein beta-8Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
HSF1-dependent transactivation
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 2

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
583.2 TPM
Cólon sigmoide
522.6 TPM
Músculo esquelético
501.7 TPM
Esôfago - Junção
499.1 TPM
Artéria tibial
307.4 TPM
OUTRAS DOENÇAS (4)
myopathy, myofibrillar, 13, with rimmed vacuolesneuronopathy, distal hereditary motor, type 2ACharcot-Marie-Tooth disease axonal type 2Ldistal hereditary motor neuropathy type 2
HGNC:30171UniProt:Q9UJY1
VAPBVesicle-associated membrane protein-associated protein B/CDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (5)
Sphingolipid de novo biosynthesisRHOG GTPase cycleRAC2 GTPase cycleRHOC GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 8

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
36.1 TPM
Brain Spinal cord cervical c-1
36.1 TPM
Tireoide
30.7 TPM
Brain Frontal Cortex BA9
28.9 TPM
Artéria tibial
26.7 TPM
OUTRAS DOENÇAS (3)
adult-onset proximal spinal muscular atrophy, autosomal dominantamyotrophic lateral sclerosis type 8amyotrophic lateral sclerosis
HGNC:12649UniProt:O95292
UBA1Ubiquitin-like modifier-activating enzyme 1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (3)
Antigen processing: Ubiquitination & Proteasome degradationDengue Virus Attachment and EntrySynthesis of active ubiquitin: roles of E1 and E2 enzymes
MECANISMO DE DOENÇA

Spinal muscular atrophy X-linked 2

A lethal infantile form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Clinical features include hypotonia, areflexia, and multiple congenital contractures.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
191.7 TPM
Útero
173.1 TPM
Fibroblastos
172.9 TPM
Cervix Endocervix
161.0 TPM
Linfócitos
156.0 TPM
OUTRAS DOENÇAS (2)
VEXAS syndromeinfantile-onset X-linked spinal muscular atrophy
HGNC:12469UniProt:P22314
DESDesminDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Striated Muscle Contraction
MECANISMO DE DOENÇA

Myopathy, myofibrillar, 1

A form of myofibrillar myopathy, a group of chronic neuromuscular disorders characterized at ultrastructural level by disintegration of the sarcomeric Z disk and myofibrils, and replacement of the normal myofibrillar markings by small dense granules, or larger hyaline masses, or amorphous material. MFM1 is characterized by skeletal muscle weakness associated with cardiac conduction blocks, arrhythmias, restrictive heart failure, and accumulation of desmin-reactive deposits in cardiac and skeletal muscle cells.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
14058.1 TPM
Cólon sigmoide
13011.1 TPM
Músculo esquelético
12069.4 TPM
Esôfago - Junção
10253.3 TPM
Coração - Ventrículo esquerdo
8346.0 TPM
OUTRAS DOENÇAS (4)
myofibrillar myopathy 1neurogenic scapuloperoneal syndrome, Kaeser typedilated cardiomyopathy 1Ifamilial isolated dilated cardiomyopathy
HGNC:2770UniProt:P17661
DYNC1H1Cytoplasmic dynein 1 heavy chain 1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
AggrephagyAmplification of signal from unattached kinetochores via a MAD2 inhibitory signalRHO GTPases Activate ForminsMitotic PrometaphaseEML4 and NUDC in mitotic spindle formation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2O

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
147.9 TPM
Cérebro - Hemisfério cerebelar
140.0 TPM
Cerebelo
129.1 TPM
Nervo tibial
80.3 TPM
Artéria tibial
78.4 TPM
OUTRAS DOENÇAS (4)
autosomal dominant childhood-onset proximal spinal muscular atrophy without contracturesCharcot-Marie-Tooth disease axonal type 2Ointellectual disability, autosomal dominant 13autosomal dominant non-syndromic intellectual disability
HGNC:2961UniProt:Q14204
ASAH1Acid ceramidaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Glycosphingolipid catabolismRegulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy
MECANISMO DE DOENÇA

Farber lipogranulomatosis

An autosomal recessive lysosomal storage disorder characterized by subcutaneous lipid-loaded nodules, excruciating pain in the joints and extremities, and marked accumulation of ceramide in lysosomes. Disease severity is variable. The most severe disease subtype is a rare neonatal form with death occurring before 1 year of age.

OUTRAS DOENÇAS (2)
spinal muscular atrophy-progressive myoclonic epilepsy syndromeFarber lipogranulomatosis
HGNC:735UniProt:Q13510
VRK1Serine/threonine-protein kinase VRK1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1A

A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum, evident upon brain imaging. PCH1A is an autosomal recessive form characterized by an abnormally small cerebellum and brainstem, central and peripheral motor dysfunction from birth, gliosis and spinal cord anterior horn cells degeneration resembling infantile spinal muscular atrophy. Additional features include muscle hypotonia, congenital contractures and respiratory insufficiency that is evident at birth.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.6 TPM
Testículo
41.3 TPM
Baço
13.9 TPM
Fibroblastos
12.9 TPM
Fallopian Tube
9.9 TPM
OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, autosomal recessive 10pontocerebellar hypoplasia type 1Apontocerebellar hypoplasia type 1microcephaly-complex motor and sensory axonal neuropathy syndrome
HGNC:12718UniProt:Q99986
FBXO38F-box only protein 38Disease-causing germline mutation(s) inRestrito
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 6

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
31.0 TPM
Útero
27.6 TPM
Cervix Endocervix
26.6 TPM
Artéria tibial
26.3 TPM
Linfócitos
25.6 TPM
OUTRAS DOENÇAS (2)
neuronopathy, distal hereditary motor, type 2Ddistal hereditary motor neuropathy type 2
HGNC:28844UniProt:Q6PIJ6
ATP7ACopper-transporting ATPase 1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
Detoxification of Reactive Oxygen Species
MECANISMO DE DOENÇA

Menkes disease

An X-linked recessive disorder of copper metabolism characterized by generalized copper deficiency. MNKD results in progressive neurodegeneration and connective-tissue disturbances: focal cerebral and cerebellar degeneration, early growth retardation, peculiar hair, hypopigmentation, cutis laxa, vascular complications and death in early childhood. The clinical features result from the dysfunction of several copper-dependent enzymes. A mild form of the disease has been described, in which cerebellar ataxia and moderate developmental delay predominate.

OUTRAS DOENÇAS (4)
occipital horn syndromeX-linked distal spinal muscular atrophy type 3Menkes diseaseHirschsprung disease
HGNC:869UniProt:Q04656
ALS2AlsinDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
RAC1 GTPase cycleRAB GEFs exchange GTP for GDP on RABs
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 2

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

OUTRAS DOENÇAS (4)
infantile-onset ascending hereditary spastic paralysisjuvenile primary lateral sclerosisamyotrophic lateral sclerosis type 2, juvenilejuvenile amyotrophic lateral sclerosis
HGNC:443UniProt:Q96Q42
HSPB1Heat shock protein beta-1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (4)
VEGFA-VEGFR2 PathwayExtra-nuclear estrogen signalingAUF1 (hnRNP D0) binds and destabilizes mRNAMAPK6/MAPK4 signaling
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2F

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Onset of Charcot-Marie-Tooth disease type 2F is between 15 and 25 years with muscle weakness and atrophy usually beginning in feet and legs (peroneal distribution). Upper limb involvement occurs later.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
4133.9 TPM
Aorta
3780.0 TPM
Vagina
3375.9 TPM
Artéria tibial
2663.4 TPM
Artéria coronária
2497.0 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease axonal type 2Fneuronopathy, distal hereditary motor, type 2Bdistal hereditary motor neuropathy type 2
HGNC:5246UniProt:P04792
TSEN15tRNA-splicing endonuclease subunit Sen15Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
tRNA processing in the nucleus
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 2F

A neurodevelopmental disorder characterized by progressive microcephaly, cognitive and motor delay, poor or absent speech, seizures, and spasticity. PCH2F inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
51.4 TPM
Brain Spinal cord cervical c-1
42.9 TPM
Linfócitos
39.4 TPM
Cólon sigmoide
33.2 TPM
Útero
32.2 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 2Fpontocerebellar hypoplasia type 2
HGNC:16791UniProt:Q8WW01
EXOSC8Exosome complex component RRP43Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1C

A severe autosomal recessive neurodegenerative disease characterized by cerebellar and corpus callosum hypoplasia, abnormal myelination of the central nervous system, and spinal motor neuron disease. Affected individuals manifest failure to thrive, severe muscle weakness, spasticity and psychomotor retardation. Vision and hearing are impaired.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.2 TPM
Testículo
43.8 TPM
Ovário
40.4 TPM
Cervix Endocervix
38.1 TPM
Fallopian Tube
37.8 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Cpontocerebellar hypoplasia type 1
HGNC:17035UniProt:Q96B26
SORDSorbitol dehydrogenaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Fructose biosynthesisFormation of xylulose-5-phosphate
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 8

An autosomal recessive disorder characterized by motor axonal neuropathy, slowly progressive distal muscle weakness mainly affecting the lower limbs, difficulty walking, and increased serum sorbitol. Additional variable features are distal sensory impairment, upper limb tremor, scoliosis, and mild hearing loss.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
104.5 TPM
Próstata
64.2 TPM
Fígado
49.8 TPM
Glândula adrenal
13.1 TPM
Skin Not Sun Exposed Suprapubic
12.9 TPM
OUTRAS DOENÇAS (1)
neuronopathy, distal hereditary motor, autosomal recessive 8
HGNC:11184UniProt:Q00796
C9orf72Guanine nucleotide exchange factor C9orf72Disease-causing germline mutation(s) inTolerante
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 1

An autosomal dominant neurodegenerative disorder characterized by adult onset of frontotemporal dementia and/or amyotrophic lateral sclerosis in an affected individual. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (1)
frontotemporal dementia and/or amyotrophic lateral sclerosis 1
HGNC:HGNC:28337UniProt:Q96LT7
TRIP4Activating signal cointegrator 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA
MECANISMO DE DOENÇA

Spinal muscular atrophy with congenital bone fractures 1

An autosomal recessive neuromuscular disorder characterized by prenatal-onset spinal muscular atrophy, multiple congenital contractures consistent with arthrogryposis multiplex congenita, respiratory distress, and congenital bone fractures.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
32.1 TPM
Artéria tibial
26.3 TPM
Cervix Ectocervix
26.3 TPM
Nervo tibial
25.5 TPM
Skin Sun Exposed Lower leg
24.7 TPM
OUTRAS DOENÇAS (3)
spinal muscular atrophy with congenital bone fractures 1congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndromeprenatal-onset spinal muscular atrophy with congenital bone fractures
HGNC:12310UniProt:Q15650
TSEN2tRNA-splicing endonuclease subunit Sen2Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
tRNA processing in the nucleus
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 2B

A disorder characterized by an abnormally small cerebellum and brainstem, and progressive microcephaly from birth combined with extrapyramidal dyskinesia. Severe chorea occurs and epilepsy is frequent. There are no signs of spinal cord anterior horn cells degeneration.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
11.4 TPM
Ovário
11.0 TPM
Cérebro - Hemisfério cerebelar
10.4 TPM
Útero
10.0 TPM
Fibroblastos
9.8 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 2Bpontocerebellar hypoplasia type 2
HGNC:28422UniProt:Q8NCE0
SPTAN1Spectrin alpha chain, non-erythrocytic 1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
RAF/MAP kinase cascadeNCAM signaling for neurite out-growthCOPI-mediated anterograde transportInteraction between L1 and AnkyrinsCaspase-mediated cleavage of cytoskeletal proteins
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 5

A disorder characterized by seizures associated with hypsarrhythmia, profound intellectual disability with lack of visual attention and speech development, as well as spastic quadriplegia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
345.3 TPM
Cerebelo
315.4 TPM
Nervo tibial
201.2 TPM
Brain Frontal Cortex BA9
191.6 TPM
Córtex cerebral
183.4 TPM
OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, autosomal dominant 11developmental and epileptic encephalopathy, 5developmental delay with or without epilepsyspastic paraplegia 91, autosomal dominant, with or without cerebellar ataxia
HGNC:11273UniProt:Q13813
ATXN2Ataxin-2Disease-causing germline mutation(s) inAltamente restrito
MECANISMO DE DOENÇA

Spinocerebellar ataxia 2

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA2 is characterized by hyporeflexia, myoclonus and action tremor and dopamine-responsive parkinsonism. In some patients, SCA2 presents as pure familial parkinsonism without cerebellar signs.

OUTRAS DOENÇAS (3)
spinocerebellar ataxia type 2amyotrophic lateral sclerosislate-onset Parkinson disease
HGNC:10555UniProt:Q99700
SMN1Survival motor neuron proteinDisease-causing germline mutation(s) inDesconhecido
VIAS BIOLÓGICAS (2)
snRNP AssemblySARS-CoV-2 modulates host translation machinery
MECANISMO DE DOENÇA

Spinal muscular atrophy 1

A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
8.3 TPM
Linfócitos
7.8 TPM
Cervix Ectocervix
7.7 TPM
Cervix Endocervix
7.6 TPM
Útero
6.8 TPM
OUTRAS DOENÇAS (4)
spinal muscular atrophy, type IVspinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:11117UniProt:Q16637
BSCL2SeipinDisease-causing germline mutation(s) inTolerante
MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 2

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Inheritance is autosomal recessive.

OUTRAS DOENÇAS (5)
hereditary spastic paraplegia 17severe neurodegenerative syndrome with lipodystrophyneuronopathy, distal hereditary motor, type 5Ccongenital generalized lipodystrophy type 2
HGNC:15832UniProt:Q96G97
SEPSECSO-phosphoseryl-tRNA(Sec) selenium transferaseDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Selenocysteine synthesis
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 2D

A disorder characterized by postnatal onset of progressive atrophy of the cerebrum and cerebellum, microcephaly, profound intellectual disability, spasticity, and variable seizures.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
12.7 TPM
Intestino delgado
12.4 TPM
Nervo tibial
11.5 TPM
Ovário
10.7 TPM
Tireoide
10.6 TPM
OUTRAS DOENÇAS (3)
pontocerebellar hypoplasia type 2Dpontocerebellar hypoplasia type 2obsolete progressive cerebello-cerebral atrophy
HGNC:30605UniProt:Q9HD40
TRPV4Transient receptor potential cation channel subfamily V member 4Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cellsTRP channels
MECANISMO DE DOENÇA

Brachyolmia 3

A form of brachyolmia, a clinically and genetically heterogeneous skeletal dysplasia primarily affecting the spine and characterized by a short trunk, short stature, and platyspondyly. BCYM3 is an autosomal dominant form with severe scoliosis with or without kyphosis, and flattened irregular cervical vertebrae.

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula salivar
28.0 TPM
Esôfago - Mucosa
13.4 TPM
Rim - Córtex
13.3 TPM
Próstata
12.8 TPM
Skin Sun Exposed Lower leg
12.0 TPM
OUTRAS DOENÇAS (11)
spondyloepimetaphyseal dysplasia, Maroteaux typeneuronopathy, distal hereditary motor, autosomal dominant 8scapuloperoneal spinal muscular atrophy, autosomal dominantfamilial digital arthropathy-brachydactyly
HGNC:18083UniProt:Q9HBA0
DCTN1Dynactin subunit 1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (5)
COPI-mediated anterograde transportHSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligandMHC class II antigen presentationCOPI-independent Golgi-to-ER retrograde trafficXBP1(S) activates chaperone genes
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 14

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
212.6 TPM
Cerebelo
206.3 TPM
Brain Frontal Cortex BA9
173.9 TPM
Córtex cerebral
156.5 TPM
Pituitária
134.3 TPM
OUTRAS DOENÇAS (5)
neuronopathy, distal hereditary motor, type 7BPerry syndromeamyotrophic lateral sclerosisdistal hereditary motor neuropathy type 7
HGNC:2711UniProt:Q14203
EMILIN1EMILIN-1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Molecules associated with elastic fibres
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 10

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular diseases caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. HMND10 is characterized by length-dependent motor neuropathy primarily affecting the lower limbs, and onset of distal muscle weakness and atrophy in early childhood resulting in walking difficulties and gait abnormalities. Some affected individuals have pyramidal signs, including hyperreflexia. More variable features may include mild intellectual disability, minor gyration defects on brain imaging, foot deformities, and connective tissue defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
377.3 TPM
Cólon sigmoide
320.1 TPM
Aorta
311.6 TPM
Ovário
291.7 TPM
Artéria coronária
269.2 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (3)
neuronopathy, distal hereditary motor, autosomal dominant 10arterial tortuosity-bone fragility syndromeEMILIN-1-related connective tissue disease
HGNC:19880UniProt:Q9Y6C2
VCPTransitional endoplasmic reticulum ATPaseDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
AggrephagyAttachment and EntryAttachment and EntryAMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)ABC-family proteins mediated transport
MECANISMO DE DOENÇA

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 1

An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
229.2 TPM
Linfócitos
209.1 TPM
Músculo esquelético
193.2 TPM
Aorta
172.4 TPM
Útero
171.2 TPM
OUTRAS DOENÇAS (10)
frontotemporal dementia and/or amyotrophic lateral sclerosis 6inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1Charcot-Marie-Tooth disease type 2Yamyotrophic lateral sclerosis
HGNC:12666UniProt:P55072
CCNFCyclin-FDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 5

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS5 is an autosomal dominant form with age-dependent penetrance. Penetrance is estimated to be 50% by age 56 and 100% by age 61.

OUTRAS DOENÇAS (2)
frontotemporal dementia and/or amyotrophic lateral sclerosis 5amyotrophic lateral sclerosis
HGNC:1591UniProt:P41002
EXOSC3Exosome complex component RRP40Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1B

A severe autosomal recessive neurologic disorder characterized by a combination of cerebellar and spinal motor neuron degeneration beginning at birth. There is diffuse muscle weakness, progressive microcephaly, global developmental delay, and brainstem involvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
30.1 TPM
Testículo
28.1 TPM
Fibroblastos
21.2 TPM
Cervix Endocervix
16.4 TPM
Ovário
15.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 1Bpontocerebellar hypoplasia type 1
HGNC:17944UniProt:Q9NQT5
REEP1Receptor expression-enhancing protein 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Expression and translocation of olfactory receptors
MECANISMO DE DOENÇA

Spastic paraplegia 31, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
67.0 TPM
Cólon sigmoide
61.1 TPM
Esôfago - Muscular
51.8 TPM
Esôfago - Junção
44.2 TPM
Artéria tibial
35.6 TPM
OUTRAS DOENÇAS (4)
hereditary spastic paraplegia 31spinal muscular atrophy, distal, autosomal recessive, 6neuronopathy, distal hereditary motor, type 5Bneuronopathy, distal hereditary motor, type 5
HGNC:25786UniProt:Q9H902
RTN2Reticulon-2Disease-causing germline mutation(s) inTolerante
MECANISMO DE DOENÇA

Spastic paraplegia 12, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
105.9 TPM
Brain Frontal Cortex BA9
49.2 TPM
Córtex cerebral
48.2 TPM
Cerebelo
40.6 TPM
Cérebro - Hemisfério cerebelar
40.1 TPM
OUTRAS DOENÇAS (2)
neuronopathy, distal hereditary motor, autosomal recessive 11, with spasticityhereditary spastic paraplegia 12
HGNC:10468UniProt:O75298
BICD2Protein bicaudal D homolog 2Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
COPI-independent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Spinal muscular atrophy, lower extremity-predominant 2A, childhood onset, autosomal dominant

An autosomal dominant form of spinal muscular atrophy characterized by early-childhood onset of muscle weakness and atrophy predominantly affecting the proximal and distal muscles of the lower extremity, although some patients may show upper extremity involvement. The disorder results in delayed walking, waddling gait, difficulty walking, and loss of distal reflexes. Some patients may have foot deformities or hyperlordosis, and some show mild upper motor signs, such as spasticity. Sensation, bulbar function, and cognitive function are preserved. The disorder shows very slow progression throughout life.

OUTRAS DOENÇAS (2)
autosomal dominant childhood-onset proximal spinal muscular atrophy with contracturesspinal muscular atrophy, lower extremity-predominant, 2b, prenatal onset, autosomal dominant
HGNC:17208UniProt:Q8TD16
IGHMBP2DNA-binding protein SMUBP-2Disease-causing germline mutation(s) inTolerante
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 1

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
48.4 TPM
Cólon sigmoide
33.5 TPM
Esôfago - Junção
31.9 TPM
Útero
29.7 TPM
Cerebelo
29.6 TPM
OUTRAS DOENÇAS (2)
autosomal recessive distal spinal muscular atrophy 1Charcot-Marie-Tooth disease axonal type 2S
HGNC:5542UniProt:P38935
WARS1Tryptophan--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 9

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND9 is characterized by juvenile onset of slowly progressive distal muscle weakness and atrophy affecting both the lower and upper limbs.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 9neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalitiesautosomal recessive primary microcephalycomplex neurodevelopmental disorder
HGNC:12729UniProt:P23381
CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 2

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (5)
lower motor neuron syndrome with late-adult onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 2autosomal dominant mitochondrial myopathy with exercise intoleranceamyotrophic lateral sclerosis
HGNC:15559UniProt:Q8WYQ3
VWA1von Willebrand factor A domain-containing protein 1Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Neuronopathy, hereditary motor, autosomal recessive 7

An autosomal recessive, neuromyopathic disorder that manifests in childhood or adulthood with proximal and distal muscle weakness predominantly of the lower limbs. Affected individuals have difficulty climbing stairs and problems standing on the heels. Most patients have foot deformities, and some may have leg muscle atrophy. Muscle biopsy and electrophysiologic studies are consistent with both a myopathic process and an axonal motor neuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
196.9 TPM
Próstata
99.7 TPM
Bladder
93.6 TPM
Esôfago - Muscular
81.6 TPM
Cólon sigmoide
79.6 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
neuronopathy, distal hereditary motor, autosomal recessive 7neuronopathy, distal hereditary motor, autosomal recessive 5
HGNC:30910UniProt:Q6PCB0
SLC5A7High affinity choline transporter 1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (2)
SLC-mediated bile acid transportAcetylcholine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 7

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND7 is characterized by onset in the second decade of progressive distal muscle wasting and weakness affecting the upper and lower limbs and resulting in walking difficulties and hand grip. There is significant muscle atrophy of the hands and lower limbs. The disorder is associated with vocal cord paresis due to involvement of the tenth cranial nerve.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cólon sigmoide
3.2 TPM
Esôfago - Junção
1.8 TPM
Brain Putamen basal ganglia
1.6 TPM
Bladder
1.6 TPM
Esôfago - Muscular
1.5 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (3)
neuronopathy, distal hereditary motor, type 7Acongenital myasthenic syndrome 20distal hereditary motor neuropathy type 7
HGNC:14025UniProt:Q9GZV3

Variantes genéticas (ClinVar)

310 variantes patogênicas registradas no ClinVar.

🧬 GARS1: GRCh37/hg19 7p14.3-12.3(chr7:29296048-47809018)x1 ()
🧬 GARS1: NM_002047.4(GARS1):c.2215G>A (p.Glu739Lys) ()
🧬 GARS1: NM_002047.4(GARS1):c.67C>T (p.Arg23Trp) ()
🧬 GARS1: NM_002047.4(GARS1):c.1699+93A>T ()
🧬 GARS1: NM_002047.4(GARS1):c.815T>G (p.Leu272Arg) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 64 variantes classificadas pelo ClinVar.

26
35
3
Patogênica (40.6%)
VUS (54.7%)
Benigna (4.7%)
VARIANTES MAIS SIGNIFICATIVAS
ALS2: NM_020919.4(ALS2):c.3047dup (p.Tyr1017fs) [Likely pathogenic]
MPZ: NM_000530.8(MPZ):c.130T>C (p.Ser44Pro) [Likely pathogenic]
ALS2: NM_020919.4(ALS2):c.3983G>A (p.Ser1328Asn) [Conflicting classifications of pathogenicity]
SLC52A3: NM_033409.4(SLC52A3):c.802C>T (p.Arg268Trp) [Conflicting classifications of pathogenicity]
MFN2: NM_014874.4(MFN2):c.475-2A>G [Pathogenic]

Vias biológicas (Reactome)

180 vias biológicas associadas aos genes desta condição.

Cytosolic tRNA aminoacylation Mitochondrial tRNA aminoacylation Synthesis of 5-eicosatetraenoic acids Atorvastatin ADME Regulation of PLK1 Activity at G2/M Transition PINK1-PRKN Mediated Mitophagy TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TBC/RABGAPs TICAM1-dependent activation of IRF3/IRF7 Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation PPARA activates gene expression Transcriptional activation of mitochondrial biogenesis Activation of PPARGC1A (PGC-1alpha) by phosphorylation Transcriptional regulation of white adipocyte differentiation SUMOylation of transcription cofactors Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Heme signaling MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Regulation of MITF-M dependent genes involved in metabolism Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression NRAGE signals death through JNK G alpha (12/13) signalling events RHOA GTPase cycle RND3 GTPase cycle RND1 GTPase cycle Vitamin B2 (riboflavin) metabolism Processing of SMDT1 Mitochondrial protein degradation Carboxyterminal post-translational modifications of tubulin Post-chaperonin tubulin folding pathway Platelet degranulation Detoxification of Reactive Oxygen Species Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation FGFR2 alternative splicing mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA SARS-CoV-1-host interactions SARS-CoV-1 modulates host translation machinery mRNA Polyadenylation Dengue Virus-Host Interactions Phase I - Functionalization of compounds Neutrophil degranulation Regulation of pyruvate metabolism Transport of Mature mRNA derived from an Intron-Containing Transcript HIV Transcription Initiation RNA Polymerase II HIV Promoter Escape Transcription of the HIV genome HATs acetylate histones RNA Polymerase II Pre-transcription Events Regulation of TP53 Activity through Phosphorylation RNA Polymerase II Promoter Escape RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Initiation And Promoter Clearance Neurodegenerative Diseases IRF3 mediated activation of type 1 IFN DDX58/IFIH1-mediated induction of interferon-alpha/beta Regulation of innate immune responses to cytosolic DNA STAT6-mediated induction of chemokines IRF3-mediated induction of type I IFN Interleukin-37 signaling TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation Negative regulators of DDX58/IFIH1 signaling Potential therapeutics for SARS SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses ABC-family proteins mediated transport Signaling by FGFR1 in disease Defective CFTR causes cystic fibrosis Signaling by plasma membrane FGFR1 fusions AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) snRNP Assembly SARS-CoV-2 modulates host translation machinery ATF4 activates genes in response to endoplasmic reticulum stress mRNA decay by 3' to 5' exoribonuclease Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA Major pathway of rRNA processing in the nucleolus and cytosol Nuclear RNA decay NOD1/2 Signaling Pathway Ub-specific processing proteases NRIF signals cell death from the nucleus p75NTR recruits signalling complexes NF-kB is activated and signals survival Neddylation Interleukin-1 signaling Pexophagy Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Nuclear events mediated by NFE2L2 ALKBH3 mediated reversal of alkylation damage tRNA processing in the nucleus HSF1-dependent transactivation Sphingolipid de novo biosynthesis RHOC GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle Synthesis of active ubiquitin: roles of E1 and E2 enzymes Antigen processing: Ubiquitination & Proteasome degradation Dengue Virus Attachment and Entry Striated Muscle Contraction Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal MHC class II antigen presentation Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane RHO GTPases Activate Formins COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic Mitotic Prometaphase AURKA Activation by TPX2 HCMV Early Events Aggrephagy EML4 and NUDC in mitotic spindle formation Glycosphingolipid catabolism Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Ion influx/efflux at host-pathogen interface Ion transport by P-type ATPases RAB GEFs exchange GTP for GDP on RABs RAC1 GTPase cycle VEGFA-VEGFR2 Pathway AUF1 (hnRNP D0) binds and destabilizes mRNA MAPK6/MAPK4 signaling Extra-nuclear estrogen signaling Fructose biosynthesis Formation of xylulose-5-phosphate ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA Caspase-mediated cleavage of cytoskeletal proteins Nephrin family interactions NCAM signaling for neurite out-growth Interaction between L1 and Ankyrins RAF/MAP kinase cascade RHOU GTPase cycle RHOV GTPase cycle Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea Selenocysteine synthesis TRP channels High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells XBP1(S) activates chaperone genes Molecules associated with elastic fibres Translesion Synthesis by POLH HSF1 activation N-glycan trimming in the ER and Calnexin/Calreticulin cycle Hedgehog ligand biogenesis Hh mutants are degraded by ERAD Josephin domain DUBs Ovarian tumor domain proteases E3 ubiquitin ligases ubiquitinate target proteins Protein methylation RHOH GTPase cycle Attachment and Entry Attachment and Entry Dengue Virus Genome Translation and Replication Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide Expression and translocation of olfactory receptors Mitochondrial protein import Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation Acetylcholine Neurotransmitter Release Cycle Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) SLC-mediated bile acid transport

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 33
2Fase 29
1Fase 112
·Pré-clínico76
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 100 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença das células dos cornos anteriores

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 29 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

47 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07844590 · Developing New Ways to Detect Respiratory Impairment Early i…Recrutando
🇺🇸 Estados Unidos
NCT07533903 · Functional Outcomes and Control Using Synchron BCI - Austral…Recrutando
NA🇦🇺 Austrália
NCT07187388 · Investigating the Impact of Electrical Stimulation on Facial…Recrutando
NA🇺🇸 Estados Unidos
NCT07543367 · INdependence Through Endovascular Neuroprosthetic Technology…Recrutando
NA🇺🇸 Estados Unidos
NCT07446114 · Functional Outcomes and Control Using Synchron BCI - CanadaRecrutando
NA🇨🇦 Canadá
NCT07478172 · Effects of Whole-body Electrical Muscle Stimulation Exercise…Recrutando
NA🇺🇸 Estados Unidos
NCT07204977 · Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyot…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07233148 · Healing ALS Registry Observational Study (HAROS)Recrutando
🇺🇸 Estados Unidos
NCT07401121 · Safety and Tolerability Study of CTx1000 In Participants Wit…Recrutando
PHASE1🇦🇺 Austrália
NCT07798700 · Biofluid Research on Age-Related or Inherited Neurodegenerat…Recrutando
🇺🇸 Estados Unidos
NCT07127172 · GB-PRIME: An Early Feasibility Study of a Precise Roboticall…Recrutando
NA🇬🇧 Reino Unido
NCT07491484 · Impact of Physical Functioning on Patient-Reported Outcomes …Recrutando
🇺🇸 Estados Unidos
NCT06992596 · UAE-PRIME: A Feasibility Study of a Precise Robotically Impl…Recrutando
NAUnited Arab Emirates
NCT06527222 · A Study of Ranolazine in ALSRecrutando
PHASE2🇺🇸 Estados Unidos
NCT06665165 · AMX0114 in Adult Participants With Amyotrophic Lateral Scler…Recrutando
PHASE1🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT06765499 · The Study Evaluating the Improvement of Nutritional Status a…Recrutando
NA🇨🇳 China
NCT07268833 · Translating Single-cell Vulnerability Into Novel ALS Biomark…Recrutando
🇮🇹 Itália
NCT06450418 · Digital App for Speech & Health MonitoringRecrutando
🇬🇧 Reino Unido
NCT06553976 · Spastic Paraplegia - Centers of Excellence Research NetworkRecrutando
🇺🇸 Estados Unidos
NCT05983211 · Quantitative and Repetitive TMS in ALS - Recruiting for Stag…Recrutando
NA🇨🇦 Canadá
NCT05744310 · Effects of Long Term Ventilation Support on the Quality of L…Recrutando
NA🇳🇴 Noruega
NCT06318598 · Biomarker-driven Phenotypic Dissection of Amyotrophic Latera…Recrutando
🇮🇹 Itália
NCT06318585 · Creation of a Clinical Database for the Study of Phenotypic …Recrutando
🇮🇹 Itália
NCT05354622 · Hereditary Spastic Paraplegia Genomic Sequencing Initiative …Recrutando
🇺🇸 Estados Unidos
NCT05237973 · Investigational Use of Neuromuscular UltrasoundRecrutando
🇺🇸 Estados Unidos
NCT03827187 · Awareness Detection and Communication in Disorders of Consci…Recrutando
NA🇮🇪 Irlanda · 🇬🇧 Reino Unido
NCT05136222 · Polysomnographic Titration of Non-invasive Ventilation in Mo…Recrutando
NA🇦🇺 Austrália
NCT04944940 · Clinical, Molecular and Imaging Biomarkers in Spinal and Bul…Recrutando
🇺🇸 Estados Unidos
NCT05204017 · Comprehensive Analysis Platform To Understand, Remedy and El…Recrutando
🇨🇦 Canadá
NCT05183152 · Non-invasive BCI-controlled Assistive DevicesRecrutando
NA🇺🇸 Estados Unidos
NCT05137665 · Target ALS Biomarker Study; Longitudinal Biofluids, Clinical…Recrutando
🇨🇴 Colômbia · Puerto Rico · 🇺🇸 Estados Unidos
NCT03127267 · Efficacy and Safety of Masitinib Versus Placebo in the Treat…Recrutando
PHASE3🇧🇪 Bélgica · 🇩🇰 Dinamarca · 🇫🇷 França +14
NCT04302870 · Motor Neurone Disease - Systematic Multi-Arm Adaptive Random…Recrutando
PHASE2, PHASE3🇬🇧 Reino Unido
NCT03489278 · Clinical Procedures to Support Research in ALSRecrutando
🇺🇸 Estados Unidos
NCT03225144 · Investigating Complex Neurodegenerative Disorders Related to…Recrutando
🇺🇸 Estados Unidos
NCT04706234 · Systematic Assessment of Laryngopharyngeal Function in Patie…Recrutando
🇦🇹 Áustria · 🇩🇪 Alemanha · 🇮🇱 Israel +5
NCT02567136 · Imaging Biomarkers in ALSRecrutando
🇺🇸 Estados Unidos
NCT06885918 · ALS Research CollaborativeRecrutando
🇺🇸 Estados Unidos
NCT01900132 · Electrical Impedance Myography: Natural History Studies inNe…Recrutando
NA🇺🇸 Estados Unidos
NCT01772602 · The National Amyotrophic Lateral Sclerosis RegistryRecrutando
🇺🇸 Estados Unidos
NCT04292574 · UK SMA Patient RegistryRecrutando
🇬🇧 Reino Unido
NCT00004568 · Study of Inherited Neurological DisordersRecrutando
Mali · 🇺🇸 Estados Unidos
NCT07298486 · Impact of Robotic Glove Use on Quality of Life, Grip Strengt…Por convite
NA🇺🇸 Estados Unidos
NCT07284810 · Tracking Self-Reported Functional Needs and Quality of LifePor convite
NA🇺🇸 Estados Unidos
NCT04961450 · Explore Biomarkers of Motor Neuron Disease/Frontal Dementia …Por convite
🇨🇳 China
NCT06376279 · Genetic Diagnosis in Inborn Errors of MetabolismPor convite
NCT00585572 · Wisconsin Brain Donor ProgramPor convite
🇺🇸 Estados Unidos

Outros ensaios clínicos

213 ensaios clínicos encontrados, 65 ativos.

Distribuição por fase
NCT07619300 · Dorsal Root Ganglion Stimulation After Lower Motor Neuron Da…Em breve
NA🇺🇸 Estados Unidos
NCT07794072 · Digital Patient Engagement in Technology-Supported Neuroreha…Em breve
🇮🇹 Itália
NCT07706270 · Serum Neurofilaments in the Diagnosis of Amyotrophic Lateral…Em breve
NCT07737977 · Developing a Comprehensive Biomarker Panel for Monitoring Pr…Em breve
🇫🇷 França · 🇪🇸 Espanha
NCT07396818 · Kamlanoflast In Amyotrophic Lateral SclerosisEm breve
PHASE1, PHASE2
NCT07093268 · Safety of Intrathecal Riluzole in Patients With Amyotrophic …Em breve
PHASE1🇦🇺 Austrália
NCT06645197 · An IIT Clinical Study to Evaluate the Safety, Tolerability, …Em breve
EARLY_PHASE1🇨🇳 China
NCT06541873 · Gait Patterns in Dual-task Conditions in Patients With Amyot…Em breve
NCT07838883 · Rare Disease Registry Database for Movement Disorders in Sou…Ativo
🇨🇳 China
NCT07796776 · The Aim of the Study is to Characterize Patients Exhibiting …Ativo
🇮🇹 Itália
NCT07193953 · Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Di…Ativo
PHASE1🇨🇦 Canadá
NCT06878235 · Validation of the French Version of the Primary Lateral Scle…Ativo
🇫🇷 França
NCT06643481 · A Clinical Trial to Learn About the Effects of VHB937 in Peo…Ativo
PHASE2🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +14
NCT04380649 · Development and Test of a Headset for BCI Until Obtaining an…Ativo
NA🇫🇷 França
NCT04875416 · Phenotype, Genotype and Biomarkers 2Ativo
South Africa · 🇺🇸 Estados Unidos
NCT03912987 · TRIAL READY (Clinical Trial Readiness)Ativo
🇺🇸 Estados Unidos
NCT03362658 · Novel MRI Biomarkers for Monitoring Disease Progression in A…Ativo
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT02327845 · Phenotype, Genotype & Biomarkers in ALS and Related Disorder…Ativo
🇩🇪 Alemanha · South Africa · 🇺🇸 Estados Unidos
NCT02987413 · Escalated Application of Mesenchymal Stem Cells in Amyotroph…Concluído
PHASE1🇧🇷 Brasil
NCT06740227 · Effects of Virtual Reality-Based Balance Training Compared t…Concluído
NAPakistan
NCT06315673 · Digital Assessment of Speech and Fine Motor Control in ALSConcluído
🇺🇸 Estados Unidos
NCT06421753 · Efficiency of Spatially Distributed Sequential Stimulation (…Concluído
NA🇫🇷 França
NCT06177431 · An Open Label Extension Study of Monepantel in Individuals W…Concluído
PHASE1🇦🇺 Austrália
NCT06206551 · Implementing Spiritual Care in Inpatient Palliative CareConcluído
🇩🇪 Alemanha
NCT06012110 · Transcutaneous Electrical Stimulation for Spasticity in Pati…Concluído
NA🇺🇸 Estados Unidos
NCT05508074 · Treatment Combining Riluzole and IFB-088 in Bulbar Amyotroph…Concluído
PHASE2🇫🇷 França · 🇮🇹 Itália
NCT04894240 · A Study of Monepantel in Individuals With Motor Neurone Dise…Concluído
PHASE1🇦🇺 Austrália
NCT04695210 · Virtual Peer-to-peer Support Programme for Carers of MNDConcluído
NA🇬🇧 Reino Unido
NCT05852405 · Clinical Characteristics, Natural History, Health Care Measu…Concluído
🇩🇪 Alemanha
NCT04788745 · Targeting Metabolic Flexibility in Amyotrophic Lateral Scler…Concluído
PHASE2🇦🇺 Austrália · 🇳🇱 Países Baixos · 🇬🇧 Reino Unido
NCT04939818 · Clinical Feasibility of Speech Phenotyping for Remote Assess…Concluído
🇬🇧 Reino Unido
NCT06256107 · Virtual Reality in Motor Neurone DiseaseConcluído
NA🇬🇧 Reino Unido
NCT04322149 · Multiple Doses of AT-1501-A201 in Adults With ALSConcluído
PHASE2🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT04430686 · Respiratory Complications in ALSConcluído
🇬🇧 Reino Unido
NCT04259255 · Radicava® (Edaravone) Findings in Biomarkers From ALS (REFIN…Concluído
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT05314348 · Surface EMG and Ultrasound in MNDConcluído
NA🇬🇧 Reino Unido
NCT03929068 · Sinemet for Spasticity and Function in Amyotrophic Lateral S…Concluído
PHASE1🇺🇸 Estados Unidos
NCT03792490 · Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modi…Concluído
PHASE2🇫🇷 França · 🇩🇪 Alemanha · 🇨🇭 Suíça
NCT03706391 · Study of ALS Reversals 4: LifeTime ExposuresConcluído
🇺🇸 Estados Unidos
NCT03560661 · Acoustic and Perceptual Markers of Dysarthria in Amyotrophic…Concluído
🇫🇷 França
NCT03464903 · Study of ALS Reversals 2: Genetic AnalysesConcluído
🇺🇸 Estados Unidos
NCT04293484 · Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotr…Concluído
NA🇮🇹 Itália
NCT03520517 · Open-label Study to Evaluate Safety, Tolerability and PK of …Concluído
PHASE1🇺🇸 Estados Unidos
NCT03548311 · Clinical Trial of Ultra-high Dose Methylcobalamin for ALSConcluído
PHASE3🇯🇵 Japão
NCT03293394 · Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclero…Concluído
NA🇮🇹 Itália
NCT03487263 · Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in…Concluído
PHASE1🇦🇺 Austrália
NCT03359538 · Rapamycin Treatment for ALSConcluído
PHASE2🇮🇹 Itália
NCT03356288 · The General Breathing Record StudyConcluído
🇬🇧 Reino Unido
NCT03809845 · Serial Fasciculation Measurements in Motor Neurone DiseaseConcluído
NA🇬🇧 Reino Unido
NCT03127514 · AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)Concluído
PHASE2🇺🇸 Estados Unidos
NCT03797677 · MN4000 for Treatment of CF and MND Patients in the Home Sett…Concluído
NA🇺🇸 Estados Unidos
NCT02819765 · Deep Phenotyping in Patients With ALSConcluído
🇺🇸 Estados Unidos
NCT02852278 · A Patient Centric Motor Neuron Disease Activities of Daily L…Concluído
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
3.353 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 3.353

#1

Muscle MRI and Muscle Ultrasound Applications in MND/ALS: Academic Insights and Clinical Opportunities.

European journal of neurology2026 Mar

There is an unmet need for the clinically relevant ALS biomarkers to facilitate an accurate diagnosis in suspected cases, monitor disease progression and evaluate response to therapy in clinical trials. While the MND/ALS literature is dominated by innovative brain studies, motor disability in ALS is primarily driven by neurogenic muscle change impacting mobility, dexterity, respiratory and bulbar function. With the intention of raising awareness of muscle-derived imaging markers in ALS, a systematic review has been conducted. Study designs, imaging methods, data interpretation frameworks, and cohort characteristics were systematically evaluated to identify innovative approaches and barriers to clinical implementation. A total of 219 studies were screened and 73 original studies selected for systematic review; 37 muscle MRI studies and 36 studies using ultrasound, PET or CT. All of the selected studies successfully captured ALS-associated muscle degeneration and their methods included the evaluation of muscle dimensions (thickness/volumes n = 34), 'acute' denervation (water content, n = 15), fasciculation counts (n = 14), 'chronic' neurogenic change (fat content, n = 21), metabolic changes (n = 4), diffusion alterations (n = 8) and echo intensity changes (n = 13). Despite the huge impact of lower motor neuron dysfunction on the patients' independence, survival and quality of life, muscle imaging is a glaringly overlooked frontier of MND/ALS research. This is a missed opportunity, as a variety of non-invasive quantitative muscle imaging techniques have been successfully used in other neurological conditions; these protocols are easy to implement on commercial MRI and ultrasound platforms and recent studies have demonstrated their ease of use and potential clinical utility.

#2

Historical and clinical analysis of a case of progressive muscular atrophy (1853-1871).

European neurology2026 Mar 19

This article presents the historical and clinical analysis of Auguste-Joseph Bellinghen (1818-1872), whose medical course was documented in 1853 and later published in 1871. These records provide a rare longitudinal account of a patient with progressive muscular atrophy (PMA), a condition first described by Aran in 1850 and later redefined within the spectrum of motor neuron diseases by Charcot. The 1853 manuscript depicts a 35-year-old artisan with asymmetrical weakness, fasciculations-described by the patient as a "gelatinous oscillation"-and progressive muscular wasting, while the 1871 report shows him severely disabled, socially marginalized, and institutionalized. Together, these sources illustrate both the slow, relentless course of PMA and the therapeutic practices of the time, including cauterization, sulfur baths, and electrotherapy, all of which proved ineffective. The case also reflects the evolution of nosological frameworks: from Aran's clinical description without neuropathological confirmation to Charcot's integration of anatomical lesions into disease classification, thereby laying the foundations of modern neurology. Beyond clinical insights, the documents highlight the value of hospital archives, medical iconography, and the role of interns in constructing medical memory. Bellinghen's case thus exemplifies how individual trajectories illuminate both the biological and social dimensions of chronic illness in 19th-century France, while providing historiographic depth to the early history of motor neuron disease.

#3

Paraspeckle condensation is controlled via TDP-43 polymerization and linked to neuroprotection.

Nature cell biology2026 Mar 18

The paraspeckle is a disease-relevant biomolecular condensate assembled from long non-coding RNA (lncRNA) NEAT1_2 ribonucleoprotein particles. Paraspeckle biogenesis is suppressed in normal tissues, yet it can be rapidly upregulated under stress. Here we demonstrate that a neurodegeneration-linked RNA-binding protein TDP-43 inhibits NEAT1_2 ribonucleoprotein particle condensation into the paraspeckle, in a concentration-dependent manner, which requires its intact polymerization and RNA binding. This effect is counterbalanced by core paraspeckle proteins such as FUS. Below disruptive concentrations, TDP-43 can be recruited into paraspeckles, forming non-liquid clusters. Under stress, TDP-43 sequestration into de novo nuclear condensates alleviates paraspeckle suppression and increases their dynamism. NEAT1_2 middle-part and 3'-end UG repeats mediate paraspeckle regulation by TDP-43 cotranscriptionally and post assembly, respectively. The deletion of the 3'-end UG repeat increases paraspeckle stability and cytoprotection in stressed human neurons. Consistently, longer 3'-end UG repeats are linked to shorter survival in the neurodegenerative disease amyotrophic lateral sclerosis. Thus, TDP-43 is a critical regulator of paraspeckle condensates linked to cytoprotection.

#4

Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics.

Cell reports. Medicine2026 Mar 17

Tofersen, the first approved genetically targeted therapy for amyotrophic lateral sclerosis (ALS), demonstrates significant lowering of plasma neurofilament in adults carrying mutations in the superoxide dismutase 1 (SOD1) gene; however, additional biomarkers of treatment response in ALS are lacking. Here, we analyze longitudinally collected cerebrospinal fluid (CSF) samples from the phase 3 VALOR clinical trial to identify candidate tofersen treatment-response biomarkers in SOD1-ALS via quantitative proteomics. We observe significant modulation from baseline abundance for 56 proteins in tofersen-treated participants relative to placebo, including CSF GPNMB, which is significantly and continuously elevated across all post-baseline timepoints. We orthogonally confirm this observation by GPNMB immunoassay in independent tofersen-treated cohorts. Taken together, these data identify pharmacodynamic-response biomarkers of tofersen treatment that can be measured as early as 4 weeks post-treatment in SOD1-ALS patients and demonstrate the utility of leveraging unbiased proteomic screening integrated with targeted validation methods to identify pharmacodynamic-response biomarkers in clinical trial patient samples.

#5

HML-2 env knockdown by AAV9-mediated miRNAs attenuates amyotrophic lateral sclerosis-like manifestations in mice.

Brain : a journal of neurology2026 Mar 14

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease for which there is no cure. While the precise etiology of ALS remains elusive, growing evidence suggests a pathogenic role for human endogenous retrovirus-K (HERV-K) in ALS. Expression of HERV-K subtype HML-2 envelope protein in neurons causes neurotoxicity in vitro and induces ALS-like symptoms in mice. We investigated the use of the Adeno-Associated Virus-9 (AAV9)-mediated artificial microRNA (amiRNA) targeting the HML-2 env gene in an ALS mouse model. From an in vitro screen of amiRNAs targeting the HML-2 env gene three were chosen and inserted in tandem into an AAV9 vector and validated in vitro. This approach provided robust silencing of the transgene, with tandem amiRNA achieving robust reduction in gene and protein expression levels. Its therapeutic effectiveness was tested in an HML-2 Env transgenic mouse model in which the env gene is expressed under the neuron-specific thy1 promoter and develops an ALS-like phenotype. A single intracerebroventricular injection of AAV9 vector encoding the amiRNAs into the mice at postnatal day 1 effectively reduced HML-2 Env expression in the brain and spinal cord at 84 days post-injection which was the longest time point studied. Knockdown of HML-2 env decreased the loss of cortical and spinal motor neurons and alleviated muscle fiber degeneration and fiber type grouping. This led to improved motor function. Our results provide compelling evidence supporting the use of multiple amiRNAs delivered in an AAV9 vector for treating forms of ALS linked to HML-2.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.169 artigos no totalmostrando 199

2026

Translation of the Dimensional Apathy Scale to Brazilian Portuguese to assess people living with HIV.

Dementia & neuropsychologia
2026

Why is it so difficult to discover drugs for amyotrophic lateral sclerosis? A protein intrinsic disorder perspective.

Expert opinion on drug discovery
2026

The role of N-acetylcysteine and glutathione in the management of Parkinson's disease: a systematic review of oxidative biomarkers and clinical outcomes.

Amino acids
2026

Motor Neuron Disease Mortality Trends in Australia From 1986 to 2023: A Population-Based Study.

The Medical journal of Australia
2026

Muscle MRI and Muscle Ultrasound Applications in MND/ALS: Academic Insights and Clinical Opportunities.

European journal of neurology
2026

Hirayama disease: an uncommon cause of motor neuron disease.

Arquivos de neuro-psiquiatria
2026

Historical and clinical analysis of a case of progressive muscular atrophy (1853-1871).

European neurology
2026

Paraspeckle condensation is controlled via TDP-43 polymerization and linked to neuroprotection.

Nature cell biology
2026

Multisystemic Involvement in Autosomal Recessive Cerebellar Ataxia Type 8 Having a Novel SYNE1 Nonsense Variant.

Internal medicine (Tokyo, Japan)
2026

Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics.

Cell reports. Medicine
2026

Treating age-related loss of muscle mass and function: Where should we be focusing?

The Journal of physiology
2026

HML-2 env knockdown by AAV9-mediated miRNAs attenuates amyotrophic lateral sclerosis-like manifestations in mice.

Brain : a journal of neurology
2026

Motor Neuron Disease with Guillain-Barré Syndrome? Motor Band Sign with Anti-GQ1b Antibodies.

Diagnostics (Basel, Switzerland)
2026

Impaired Acetyl-CoA Compartmentalization Drives a Futile Lipogenic-Oxidative Cycle in N88S Seipinopathy.

Cells
2026

Immune imbalance between T helper 1, T helper 17 and regulatory T cells fuels amyotrophic lateral sclerosis pathogenesis: disease trajectory, diagnosis and therapeutic implications.

Journal of neuroinflammation
2026

Motor Neuronopathy With Widespread Fasciculations in MCM3AP-Related Disorder: Clinical and Muscle MRI Insights.

Journal of the peripheral nervous system : JPNS
2026

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance (MGUS): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response.

Journal of the peripheral nervous system : JPNS
2026

Oral Health in Amyotrophic Lateral Sclerosis: Feasibility of Oral Screening and Determinants of Poor Outcomes.

Muscle & nerve
2026

Why we need to depict the structure of DNA correctly: it's so groovy.

Brain : a journal of neurology
2026

Innovation, Adaptation, and Human Dignity in Assistive Robotics in Amyotrophic Lateral Sclerosis: A Rehabilitation Medicine Perspective.

Journal of biotechnology and biomedicine
2026

Motor neuron disease can present as a paraneoplastic neurologic syndrome with various phenotypes.

Brain communications
2026

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Expanding the Motor Band Sign in Motor Neuron Disease Using 7T MRI: Visualization of Cortical Layer-Dependent Iron Deposition in the Primary Motor Cortex.

Muscle & nerve
2026

BDNF relates to prefrontal cortex activity in the context of physical exercise.

Brain research
2026

"What about me? I'm supposed to be … superhuman?": exploring staff perspectives on how to deliver high quality psychological care for people living with amyotrophic lateral sclerosis.

Neurodegenerative disease management
2026

Mapping end-of-life care for patients with neurological conditions in German hospices: a point prevalence survey.

BMJ neurology open
2026

Gadolinium enhancement of the cauda equina in a case of familial ALS with p.S135G SOD1 mutation.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Exploring the use of narrative-based approaches in individuals with amyotrophic lateral sclerosis: A narrative review.

Palliative & supportive care
2026

Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neurofilament Analyses.

Muscle & nerve
2026

Respiratory Onset Amyotrophic Lateral Sclerosis in a Patient With C9orf72 Expansion.

Journal of clinical neuromuscular disease
2026

Voltage-gating and neuronal signalling in neurodegeneration: From neuropathology to therapeutic opportunities in motor neuron disease.

Neurobiology of disease
2026

KIF5A and ALS: a clinical and genetic description of a case series and review of literature.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Imaging spectrum and diagnostic insights in Hirayama disease: A case series.

Radiology case reports
2026

Maximal motor unit firing rates decline with amyotrophic lateral sclerosis progression.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2026

Analysis and comparison of the trends in the burden of motor neuron disease in China and worldwide from 1990 to 2021.

PloS one
2026

Blood Lactate as a Prognostic Biomarker for Survival and Weight Loss in Amyotrophic Lateral Sclerosis: An Exploratory-Validation Study.

Annals of neurology
2026

Exploring Patient Perspectives on an Immersive Virtual Reality Experience for Neuromuscular Diseases.

Games for health journal
2026

Disruption of BDNF signalling in neuropathologies.

Biochemical Society transactions
2026

Standing up to neurodegeneration: evaluating autonomic stress and safety in sit-to-stand using heart rate variability analysis.

Biomedizinische Technik. Biomedical engineering
2026

Imaging-derived neuromuscular ultrasound phenotypes are associated with functional status in amyotrophic lateral sclerosis.

Journal of neurology
2026

Accuracy of clinical diagnosis in neurodegenerative diseases - a study of 455 autopsy cases.

Journal of neurology
2026

Skeletal muscle in spinal muscular atrophy: Critical insights from pathogenesis to therapeutic strategies.

Neurobiology of disease
2026

The Role of the Golgi Apparatus in Neurodegeneration.

Sub-cellular biochemistry
2026

Timing of communication and technology control support in ALS - a systematic review.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Predictive genetic testing in amyotrophic lateral sclerosis (ALS): Experiences of decision-making and engagement with UK genetic counseling services.

Journal of genetic counseling
2026

Differential inclusion formation of an aggregation-prone protein reveals differences in the proteostasis capacity of neuronal cell lines.

Biochimica et biophysica acta. Molecular cell research
2026

An implementation study of a remote monitoring platform to increase access to specialist care in motor neuron disease.

Neurodegenerative disease management
2026

Efficient induction of motor neuron disease in transgenic G93A SOD1 mice by prion-like seeding.

Prion
2026

Synaptic and cytoskeletal CSF signatures of motor neuron disease: the role of cyclase-associated protein 2.

Scientific reports
2026

Systemic immune-metabolic interactions in patients with amyotrophic lateral sclerosis: correlations of plasma cytokines with metabolic status.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Extracellular vesicles at the neuromuscular junction: messengers of synaptic health and disease.

Cell and tissue research
2026

Natural Killer Cell Dysregulation During ALS Disease Progression: A Gene Expression Analysis.

Neurology open access
2026

Can patient-reported outcome measures predict mortality in neurological populations? A systematic review.

Frontiers in neurology
2026

Myelin sheaths in the central nervous system can withstand damage and dynamically remodel.

Science (New York, N.Y.)
2026

From Dish to Trial: Building Translational Models of ALS.

Cells
2026

Four decades of ALS care: a retrospective study of epidemiology, clinical course and changes in management.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Implications of virus-induced stress granules in tauopathies.

Translational neurodegeneration
2026

Anatomical reduction for focal fasciculations in peroneus brevis spondylolisthesis: a case report suggesting a mechanism of peripherally derived tremor.

BMC musculoskeletal disorders
2026

Lost in translation: absence of KIAA1324/ELAPOR1 protein in pathological TDP-43-affected neurons in ALS/FTD.

Acta neuropathologica communications
2026

Impaired BDNF-TrkB trafficking and signalling in Down syndrome basal forebrain neurons.

Cell death & disease
2026

[Combination of amyotrophic lateral sclerosis with Alzheimer's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

Case Report: Spinal muscular atrophy with IgA nephropathy: a coincidence or association?

Frontiers in pediatrics
2026

A Systematic Review of Hyperselective Neurectomy for Management of the Spastic Upper Limb.

Hand (New York, N.Y.)
2026

Non-Cell-Autonomous Mechanisms and Systemic Interactions in Spinal Muscular Atrophy.

The American journal of pathology
2026

Changes in body composition and phase angle from diagnosis to gastrostomy, in motor neuron disease patients: a longitudinal study.

European journal of clinical nutrition
2026

Trajectory of Mobility Function Decline for People With Motor Neuron Disease.

Archives of physical medicine and rehabilitation
2026

Current and Ongoing Clinical Studies.

Muscle & nerve
2025

Age-period-cohort effect on motor neuron disease mortality in the United States, 2001-2020.

Frontiers in neurology
2026

TBK1-Associated Primary Lateral Sclerosis Followed by Right Temporal Variant Frontotemporal Dementia.

Annals of clinical and translational neurology
2026

A multi-omics study on monozygotic twins discordant for amyotrophic lateral sclerosis and literature review underline a potential role for innate immunity and epigenetic dysregulation in disease mechanisms.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

TBK1 activity regulates the directionality of axonal transport of signalling endosomes.

Life science alliance
2026

Electrodiagnostic Approach to Defects of Neuromuscular Transmission.

Muscle & nerve
2026

Crossroad of motor neuron disease and dementia: Insights from TDP-43 RNA-binding deficiency.

Neural regeneration research
2026

National and subnational burden of neurological disorders in Iran, 1990 to 2021: results from the global burden of disease study 2021.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

A national survey of pseudobulbar affect and symptomatic treatment in Amyotrophic Lateral Sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Prevalence and Clinical Associations of A-Waves in Routine Nerve Conduction Studies: A Retrospective Analysis.

Noro psikiyatri arsivi
2026

The spinal and bulbar muscular atrophy-health index: a disease-specific outcome measure.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Molecular Characterization of Calu-3 Cells from Submerged to Air-Liquid Interface to Model Lung Infections.

Journal of proteome research
2026

Pleiotrophin/Midkine Pathway Is Dysregulated in a TDP-43A315T Mouse Model of Amyotrophic Lateral Sclerosis (ALS).

Neuropathology : official journal of the Japanese Society of Neuropathology
2026

ABCA1 acts as a protective modulator in amyotrophic lateral sclerosis.

iScience
2026

The genetics of autosomal recessive ALS: a review of the common forms and their phenotypes.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Targeting Non-coding RNAs in Neurodegeneration: Advances in Therapeutic RNA Modalities and Next-Gen Delivery Technologies.

Current Alzheimer research
2025

Exploring rare coding variants in UK biobank: preliminary associations with motor neuron disease.

Frontiers in aging neuroscience
2026

Pain and fatigue in amyotrophic lateral sclerosis: a multiple methods study.

Neurodegenerative disease management
2026

Reduced osteogenic factors and early osteoblast senescence in SOD1(G93A) ALS mouse model.

JCI insight
2026

Liver Steatosis in Induced Hepatocytes From Carriers of Spinal Muscular Atrophy.

Muscle & nerve
2026

Addendum to the 2023 clinical practice guidelines for amyotrophic lateral sclerosis in Japan: approval and integration of novel disease-modifying therapies.

Rinsho shinkeigaku = Clinical neurology
2026

Development and validation of predictive models for 6-month gastrostomy timing in amyotrophic lateral sclerosis.

BMJ neurology open
2026

Long-Term Exposure to Air Pollution and Risk and Prognosis of Motor Neuron Disease.

JAMA neurology
2026

Air Pollution and Motor Neuron Disease-Particulate-ly Risky.

JAMA neurology
2026

Expanding the neurological spectrum of HTLV-1 beyond HAM/TSP: a contemporary perspective.

Lancet regional health. Americas
2026

LAMP1 and LAMP2A localise to axonal organelles with distinct motility dynamics and partially overlapping molecular signatures in human neurons.

Journal of cell science
2026

WDR62 is required for proper proliferation and early differentiation of skeletal myoblasts.

Communications biology
2025

Establishing Diagnostic and Differential Diagnostic Criteria for Amyotrophic Lateral Sclerosis.

Journal of clinical medicine
2026

Heterogeneous phenotype and cardiovascular comorbidities in Swedish patients with spinobulbar muscular atrophy.

Journal of neurology
2026

Demographic, clinical and genetic characteristics of patients with amyotrophic lateral sclerosis from two specialised centres in Austria.

Journal of neurology
2026

Neuroinvasive West Nile Virus Presenting as Subacute Progressive Quadriparesis and Intractable Pain: A Case Report.

Case reports in neurological medicine
2026

Frontotemporal dementia: Clinical aspects, genetics, and neuropathology of a family with a C9ORF72 expansion in Argentina.

Brain pathology (Zurich, Switzerland)
2025

PBX-dependent and independent Hox programs establish and maintain motor neuron terminal Identity.

bioRxiv : the preprint server for biology
2025

Lysosomal escape and TMEM106B fibrillar core determine TDP-43 seeding outcomes.

bioRxiv : the preprint server for biology
2026

Microglia in C9orf72-associated amyotrophic lateral sclerosis: More or less active?

Neural regeneration research
2026

Prevalence and trajectories of post-COVID-19 neuromuscular conditions: A systematic-review and meta-analysis.

Journal of the neurological sciences
2026

Dropped head syndrome leading to the diagnosis of antisynthetase syndrome: a motor neuron mimicker.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Investigating the pathogenic role of calpain proteases and the therapeutic potential of their inhibition in mice modelling Machado-Joseph disease.

Human molecular genetics
2026

Prioritizing neuropsychological research and care in Amyotrophic Lateral Sclerosis (ALS): building an international neuropsychological framework for ALS.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

Foot that spoke first: microvascular signs of a motor neuron disease.

Archives of disease in childhood
2026

Microglial HVCN1 Deficiency Improves Movement and Survival of SOD1G93A ALS Mice by Enhancing Microglial Migration and Neuroprotection.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Co-aggregation of annexin A11 and TDP-43 in FTLD/MND with primary lateral sclerosis phenotype.

Acta neuropathologica communications
2026

AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model.

Journal of biomedical science
2026

Hereditary transthyretin amyloidosis with hand weakness and bulbar involvement.

Practical neurology
2025

Human Mutant Dynactin Subunit 1 Causes Profound Motor Neuron Disease Consistent with Possible Mechanisms Involving Axonopathy, Mitochondriopathy, Protein Nitration, and T-Cell-Mediated Cytolysis.

Biomolecules
2026

Motor band sign in 18F-FDG PET/CT studies: a biomarker of degenerative upper motor neuron disease? A study of three cases and literature review.

Neurologia
2025

MAPT p.V363I mutation in a patient with presenile dementia and late amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2025

Body Weight and Range of Motion as Predictors of Trunk Asymmetry in Children With Spinal Muscular Atrophy: A Prospective Functional Assessment.

Medical science monitor : international medical journal of experimental and clinical research
2025

SOD1 mutations in Taiwanese ALS patients: Clinical characteristics, frequency, and a p.T138R founder effect.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2025

Incidence of MND in Canterbury, New Zealand and impact of a key worker role on hospital admissions.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2025

DYNC1H1 in Spinal Muscular Atrophy: Diagnostic Findings From Two Families and a Comprehensive Review of Its Role in Neuromuscular and Neurodevelopmental Disorders.

Molecular genetics & genomic medicine
2025

Synaptic changes contribute to persistent extra-motor behaviour deficits in amyotrophic lateral sclerosis.

Acta neuropathologica communications
2025

Predicting Phenoconversion to Clinically Manifest ALS: Results of a Large-Scale Proteomic Study.

medRxiv : the preprint server for health sciences
2026

Hippocampal Subfield Integrity and Age-Driven Neural Correlates of Appetite Loss in Amyotrophic Lateral Sclerosis.

Journal of magnetic resonance imaging : JMRI
2025

10H-phenothiazine exerts beneficial effects in spinal muscular atrophy in vitro and in vivo models.

Scientific reports
2026

A 10-year service evaluation of a multidisciplinary neuro-palliative care model in motor neuron disease: Impact on palliative care service delivery & advance care planning.

Palliative medicine
2025

Age-dependent removal of Atg9-containing vesicle accumulations in motoneuron disease models by physical exercise.

Translational neurodegeneration
2025

Role of Neuronal Cholecystokinin Receptor: An Emerging Therapeutic Target for Ameliorating Neurological Diseases.

Molecular neurobiology
2026

Clinical relevance of zebrafish for gene variants testing. Proof-of-principle with SMN1/SMA.

EMBO molecular medicine
2025

Biomarkers in ALS trials: from discovery to clinical utility.

Frontiers in neuroscience
2025

U7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral Sclerosis.

bioRxiv : the preprint server for biology
2025

Cell type-specific functions of the PBAF chromatin-remodeling complex in neuronal diversification.

Nature communications
2025

Protocol for applying expansion microscopy to the study of mammalian neuromuscular junctions.

STAR protocols
2026

Targeted BDNF upregulation via upstream open reading frame disruption.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

Multi-omics analyses identify potential epigenetic loci associated with survival in amyotrophic lateral sclerosis across diverse populations.

EBioMedicine
2026

Heteroaggregation of Wild-Type and ALS Mutant SOD1.

ACS chemical neuroscience
2025

Trends in motor neuron disease mortality in the United States from 1999 to 2020.

Neurodegenerative disease management
2025

Extracellular Matrix Remodeling in Motor Neuron Diseases.

International journal of molecular sciences
2025

Digital App for Speech and Health Monitoring Study (DASH): protocol for a prospective longitudinal case-control observational study for developing speech datasets in neurodegenerative disorders and dementia.

BMJ open
2025

Early assessment in bulbar-onset amyotrophic lateral sclerosis detects similar rates of nocturnal desaturation and orthopnoea compared to non-bulbar-onset disease.

Sleep & breathing = Schlaf & Atmung
2026

Insights and considerations on predicting cognitive and behavioral disturbances in MND with pure motor onset.

Journal of the neurological sciences
2025

Case Series Assessing the Use of Levetiracetam for Gait Improvement in Primary Lateral Sclerosis.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2025

Human TDP-43 overexpression in zebrafish motor neurons triggers MND-like phenotypes through gain-of-function mechanism.

Acta neuropathologica communications
2025

Movement Related Beta-Band Modulation with OPM-MEG: A Pilot Study.

Brain topography
2025

SYNE1 Deficiency Manifesting Primarily With Motor Neuron Disease.

Neurology. Genetics
2026

Emergent technologies and applications of TMS and TMS-EEG in clinical neurophysiology for early and differential diagnosis: IFCN handbook chapter.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2026

Startle Reflex in Primary Lateral Sclerosis (PLS): A Comparison With Amyotrophic Lateral Sclerosis (ALS).

Muscle & nerve
2026

The Epidemiology of Primary Lateral Sclerosis: Results from a Population-Based Cohort.

Annals of neurology
2025

Global vs. segmental acoustic features for dysarthria assessment in motor neuron diseases.

Computers in biology and medicine
2026

Physical Therapist Interventions for People With Amyotrophic Lateral Sclerosis Across Disease Stages: A Systematic Review of Efficacy.

Physical therapy
2025

SLP2/PHB Aggregates in ALS Mouse Models and Patients: Implications Beyond CHCHD10-Associated Motor Neuron Disease.

International journal of molecular sciences
2025

Amyotrophic Lateral Sclerosis (ALS)-Related Mortality Among World Trade Center-Exposed and Non-World Trade Center-Exposed Rescue and Recovery Workers.

International journal of environmental research and public health
2025

Venom Peptides Across Asian and American Tarantulas Utilize Dual Pharmacology to Target Activation and Fast Inactivation of Voltage-Gated Sodium Channels.

Toxins
2025

Mills' syndrome and myasthenia gravis: a case report.

Neuromuscular disorders : NMD
2026

Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy.

Nature neuroscience
2025

Amyotrophic lateral sclerosis in Saudi Arabia: a multicenter descriptive study.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2026

IsomiR utility in amyotrophic lateral sclerosis prognostication.

Med (New York, N.Y.)
2025

The genetic architecture of primary lateral sclerosis in a cohort of Italian patients.

Journal of neurology
2025

Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms.

Frontiers in immunology
2025

Analytical and clinical validation of step counting method in people living with amyotrophic lateral sclerosis.

Scientific reports
2025

Apathy self-awareness and its neural correlates in Parkinson's Disease.

NPJ Parkinson's disease
2025

Synaptopathy in the TDP-43ΔNLS Mouse Model of Sporadic Amyotrophic Lateral Sclerosis.

The European journal of neuroscience
2025

Role of 2-[18F]FDG-PET as a biomarker of upper motor neuron involvement in amyotrophic lateral sclerosis.

Journal of neurology
2025

Mifepristone alone and in combination with scAAV9-SMN1 gene therapy improves disease phenotypes in Smn2B/- spinal muscular atrophy mice.

Scientific reports
2025

An Autopsy Case of ALS Which Clinically Presented Sporadic Adult-Onset Lower Motor Neuron Disease and Genetically Had p. Leu127Ser (L126S) Variant in SOD1 and SMN2 Deletion.

Neuropathology : official journal of the Japanese Society of Neuropathology
2025

Validation of the dimensional apathy scale and predictors of apathy in stroke survivors.

Scientific reports
2025

The structure, redox chemistry and motor neuron toxicity of heterodimeric zinc-deficient SOD1-implications for the toxic gain of function observed in ALS.

Neurobiology of disease
2025

Expanding the spectrum of annexin A11 proteinopathy in frontotemporal lobar degeneration and motor neuron disease.

Acta neuropathologica
2025

Spinocerebellar Ataxia Type 3 Accompanied by Amyotrophic Lateral Sclerosis: A Case Report and Comprehensive Literature Review.

Internal medicine (Tokyo, Japan)
2025

The global burden of motor neuron disease: a systematic and additional analysis of global burden disease study 2021.

Orphanet journal of rare diseases
2025

Protocol for in vivo assessment of glucose metabolism in mouse models.

STAR protocols
2026

Facial onset sensory and motor neuronopathy: a diagnostic challenge.

Acta neurologica Belgica
2026

CRISPR/Cas9 gene editing in muscle-related genetic disorders: Restoring function and exercise capacity.

Tissue & cell
2026

Early brain-wide disruption of sleep microarchitecture in amyotrophic lateral sclerosis.

The Journal of clinical investigation
2025

Unraveling the genetic landscape of ALS in Greece: identification of known and novel causative variants in a 353-patient cohort.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2025

ALSUntangled #81: Pyridostigmine (mestinon®).

Amyotrophic lateral sclerosis & frontotemporal degeneration
2025

Prevalence of living alone with dementia and other progressive neurological conditions: findings from primary care data in England.

BMC medicine
2025

DTI changes of brachial plexus nerve roots in amyotrophic lateral sclerosis and their correlation with electrophysiology.

European radiology experimental
2025

Efficacy and safety of risdiplam in adults with 5q-associated spinal muscular atrophy: a nationwide observational cohort study in Austria.

EClinicalMedicine
2025

RYR 1 Gene Mutation in Motor Neuron Disease: A 10-Year Case Observation.

Case reports in neurological medicine
2026

Rehabilitation in Neuromuscular Diseases: Best Turkish Practice Recommendations by Multidisciplinary Experts.

Acta neurologica Belgica
2025

Examining the impact and role of lipid classes on the risk of amyotrophic lateral sclerosis (ALS) onset: a systematic review and GRADE analysis of the evidence.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2025

TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS/FTD.

Nature neuroscience
2025

Edaravone for amyotrophic lateral sclerosis.

Australian prescriber
2025

Clinical Reasoning and Diagnostic Challenge in a 23-Year-Old Man With Rapidly Progressive Dysphagia and Hypophonia: Juvenile-Onset Amyotrophic Lateral Sclerosis Caused by a FUS Gene Mutation.

Cureus
2025

Dynamometric measurement of hand grip and pinch strength as functional independency outcome in neuromuscular diseases.

European journal of physical and rehabilitation medicine
2025

The Other Side of the Same Coin: Beyond the Coding Region in Amyotrophic Lateral Sclerosis.

Pharmaceuticals (Basel, Switzerland)
2025

Emerging Approaches to Mitigate Neural Cell Degeneration with Nanoparticles-Enhanced Polyelectrolyte Systems.

Membranes
2025

Acceptance and Commitment Therapy for people living with motor neuron disease: the COMMEND feasibility study and randomised controlled trial.

Health technology assessment (Winchester, England)
2026

Hirayama disease: A case report.

Radiology case reports
2025

Structure and Molecular Basis for Inhibiting Human SOD1 Aggregation by a Promising Decan Derivative Modulator: A Potential Therapeutic Strategy for Treating Amyotrophic Lateral Sclerosis (ALS).

ACS chemical neuroscience
2026

Self-reported initiation apathy is related to worse quality of life in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration
2025

TDP-43 loss induces cryptic polyadenylation in ALS/FTD.

Nature neuroscience
2025

TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes.

Nature neuroscience
2025

Unraveling the Military Service-MND Connection: Time Frame, Exposures, and Phenotypic Considerations.

European journal of neurology
2025

[A case of adult-onset Krabbe disease diagnosed by galactocerebrosidase gene mutations, presenting with an atypical phenotype].

Rinsho shinkeigaku = Clinical neurology
2025

Rethinking ALS: Current understanding and emerging therapeutic strategies.

AIMS neuroscience
2025

Conditional ATXN2L-Null in Adult Frontal Cortex CamK2a+ Neurons Does Not Cause Cell Death but Restricts Spontaneous Mobility and Affects the Alternative Splicing Pathway.

Cells
2025

Is TREM2 a Stretch: Implications of TREM2 Along Spinal Cord Circuits in Health, Aging, Injury, and Disease.

Cells
2025

Integrative treatment of the motor neuron disease amyotrophic lateral sclerosis, efficacy of pharmacotherapy, traditional Chinese medicine and importance of respiratory support, life-style, and gastrostomy-assisted nutrition: A review.

International journal of clinical pharmacology and therapeutics
2025

Unraveling the Potential of Stem Cell Therapy in Motor Neuron Disease: A Narrative Review.

CNS & neurological disorders drug targets
2025

Beyond motor neurons: autonomic dysfunction and ECG findings in adults with 5q-spinal muscular atrophy.

Journal of neurology
2025

[Clinical analysis of a motor neuron disease-like phenotype associated with anti-IgLON5 disease].

Zhonghua nei ke za zhi
Ver todos os 2.169 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença das células dos cornos anteriores.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Doença das células dos cornos anteriores e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

Trata-se de uma doença neurológica que compromete as células nervosas responsáveis pela execução dos movimentos corporais. Ela se manifesta por meio de perda progressiva de força muscular, rigidez e sintomas associados.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:98503
    Orphanet
  2. GARD:19477
    GARD (NIH)
  3. Q3221083
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Doença das células dos cornos anteriores. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/doenca-das-celulas-dos-cornos-anteriores

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Doença das células dos cornos anteriores

ORPHA:98503 · MONDO:0020128
🇧🇷 Brasil SUS
SIGTAP
2 procedimentos
Geral
CID-10
G12.2 · Doença do neurônio motor
CID-11
Ensaios
65 ativos
MedGen
UMLS
C0085084
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Rara